MedicalPoint International Hospital Spec. Ulvi Samadzade Neurology

Spec. Ulvi Samadzade, M.D.

MedicalPoint Izmir Hospital
Neurology

Request Call Back

Please enable JavaScript in your browser to complete this form.
Name

Education and Expertise

  • 2010–2016 Azerbaijan State Medical University
  • 2017–2018 Gazi University Faculty of Medicine
  • 2019–2025 Dokuz Eylul University Hospital, Department of Neurology

Diseases Treated

  • Alzheimer’s Disease

  • Headaches

  • Dizziness

  • Dementia Disorders

  • Epilepsy

  • Movement Disorders (Tremors, Wilson’s Disease, Dystonia, Chorea, Ataxias)

  • Stroke – Paralysis

  • Migraine

  • Myopathies

  • Multiple Sclerosis

  • Myasthenia Gravis

  • Neuromuscular Junction Disorders

  • Parkinson’s Disease

  • Peripheral Nervous System Disorders

  • Tremors

Treatment Methods

  • Botulinum Toxin Injections

  • Intravenous Immunoglobulin (IVIG) Therapy

  • Migraine Vaccine

  • Advanced-Stage Parkinson’s Disease Treatments

  • Plasmapheresis

Experience

  • İzmir University of Economics Medical Point Hospital (2025 – Present)

Professional Memberships

  • Multiple Sclerosis Research Association

  • Turkish Neurological Society

  • European Academy of Neurology

  • The International Parkinson and Movement Disorder Society (MDS)

Research Publications

Articles Published in International Journals:

  • Baba C., Kaya E., Ozcelik S., Ozdogar A.T., Samadzade U., et al. COVID-19 vaccine response in Neuromyelitis Optica Spectrum Disorder. Clinical Neurology and Neurosurgery, Vol. 238, 2024, pp. 108152. (SCI-Expanded)

  • Baba C., Ozcelik S., Kaya E., Samadzade U., et al. Three doses of COVID-19 vaccines in multiple sclerosis patients treated with disease-modifying therapies. Multiple Sclerosis and Related Disorders, Vol. 68, 2022, pp. 104119. (SCI-Expanded)

  • Baba C., Yavas I., Samadzade U., Ozdogar A.T., et al. What might the COVID-19 pandemic in regard to people with neuromyelitis optica spectrum disorder teach us regarding the future? Clinical and Experimental Neuroimmunology, Vol. 15(1), 2024, pp. 40–44. (Scopus)

  • Ozakbas S., Baba C., Yavas I., Samadzade U., et al. Is disease-modifying therapy use in multiple sclerosis a risk factor during the COVID-19 pandemic? Journal of Health Policy and Outcomes Research, Vol. 2024(1), pp. 41–49. (Scopus)

  • Kaya E., Samadzade U., Zengin E.S., Ozakbas S. Autoimmune thyroiditis and its impact on the clinical course of multiple sclerosis: A retrospective cohort study. Mult Scler Relat Disord. 2025 Mar; 95:106341. DOI: 10.1016/j.msard.2025.106341. Epub 2025 Feb 18. PMID: 39999593.

Conference Presentations

  • Bladder dysfunction and associated factors in people with neuromyelitis optica spectrum disorder. Samadzade U., et al. ECTRIMS 2023, Milan, Italy, 11–13 October 2023.

  • Impact of Early Treatment Modification on Long-Term Outcomes in Treatment-Naive MS Patients. Samadzade U., et al. ECTRIMS 2024, Copenhagen, Denmark.

  • Epilepsy Prevalence and Characteristics in MS Patients. Kaya E., Samadzade U., et al. ECTRIMS 2024, Copenhagen, Denmark.

  • Determinants of Postpartum Relapse in MS. Alizada S., Samadzade U., et al. ECTRIMS 2024, Copenhagen, Denmark.

  • Cognitive Fatigue During Relapse and Remission in MS. Ozakbas S., Samadzade U., et al. ECTRIMS 2024, Copenhagen, Denmark.

  • Immune Response to SARS-CoV-2 Vaccines in Treatment-Naive MS Patients. Ozakbas S., Samadzade U., et al. ECTRIMS 2022, Amsterdam, Netherlands.

  • Basilar Tip Syndrome: Two Case Reports. Samadzade U., et al. 59th National Neurology Congress, Antalya, Turkey, 2023.

  • A Case of Encephalopathy Possibly Due to Lithium Intoxication. Samadzade U., Yaka E. 58th National Neurology Congress, Antalya, Turkey, 2022.

  • Coexistence of Acute Cerebral Ischemia and Acute Myocardial Infarction. Samadzade U., et al. 58th National Neurology Congress, Antalya, Turkey, 2022.

  • Aneurysmal SAH and Reversible Cerebral Vasoconstriction Syndrome. Samadzade U., et al. 19th Headache Winter School, Istanbul, Turkey, April 2023.

  • Impact of Diagnosis and Treatment Timing on Long-Term MS Outcomes. Ozakbas S., Samadzade U., et al. ECTRIMS 2024, Copenhagen, Denmark.

  • Natalizumab Safety in Women with MS: Real-World Data. Simsek Y., Samadzade U., et al. ECTRIMS 2024.

  • Physical and Clinical Condition in MS Patients Recovering from COVID-19. Ozakbas S., Samadzade U., et al. MSMilan 2023.

  • Impact of Disability Level and Disease Duration on Cognitive Function in MS. Yigit P., Samadzade U., et al. MSMilan 2023.

  • Cognitive Impairment and Chronic Neuropathic Pain in MS. Karakas H., Samadzade U., et al. MSMilan 2023.

  • Pregnancy, Breastfeeding, and Multiple Sclerosis: Attitudes of Women. Simsek Y., Samadzade U., et al. MSMilan 2023.